Overview:

Welcome to the third year of SynBioBeta London where the synthetic biology community will gather to hear from the companies commercializing their cutting edge research. Join the entrepreneurs and thought-leaders infusing new biological technologies into the bioeconomy. The event is being hosted by SynbiCITE, the Innovation and Knowledge Centre at Imperial College London dedicated to promoting the adoption and use of synthetic biology by industry.

Who Should Attend?

  • Startups: Meet the investors ready to fund your team.
  • Industry: Network with industry leaders and potential partners.
  • Investors: Meet the new startups on the scene.
  • Partners & Tech Scouts: Learn about the latest technology in the field.
  • Academics, Students & Biohackers: Follow the path to commercializing your IP.

SynBioBeta London 2015

Date & Location:

April 22, 2015 - April 23, 2015
12:30 pm - 6:00 pm

Imperial College London
Venue Information

Testimonials

Emily Leproust

A conference not to be missed — this is the place for SynBio power users, experts, key opinion leaders, investors, vendors, students and novices.

Emily Leproust, CEO, Twist Bioscience

Bethan Wolfenden

“We made several valuable connections, including to two potential investors, and a number of future customers.”

Bethan Wolfenden,
Bento Bioworks

Lionel Clarke

“SynBioBeta brings together many of the most innovative minds in the field of Synthetic Biology, sharing their enthusiasm and energy for turning ideas into reality.”

Lionel Clarke, Co-Chair
UK Synthetic Biology Leadership Council

Sponsors:

Platinum

Gold

Silver

Bronze

Event Hosts:

Speakers

Alex Pudney

Alex Pudney
ZuvaSyntha

Alexandre Zanghellini

Alexandre Zanghellini
Arzeda

Alexandra Daisy Ginsberg

Alexandra Daisy Ginsberg
Royal College of Art

Andrew Hessel

Andrew Hessel
Autodesk

Andrew Phillips

Andrew Phillips
Microsoft Research

Andy Smith

Andy Smith
Mann Bioinvest

Antony Evans

Antony Davis
TAXA

Axel Trefzer

Axel Trefzer
Thermo Fisher

Basil Omar

Basil Omar
CHAIN Biotech

Bethan Wolfenden

Bethan Woldenden
Bento Bioworks

Brynne Stanton

Brynne Stanton
Ginkgo Bioworks

Cathal Garvey

Cathal Garvey
SOSVentures

Chris Thorne

Chris Thorne
Horizon Discovery

Christine Gould

Christine Gould
Syngenta

Connor Dickie

Connor Dickie
Synbiota

David McElroy

David McElroy
Ingenza

Debra Conway

Debra Conway
CyBio

Elizabeth Nickerson

Elizabeth Nickerson
Gen9

Emily Leproust

Emily Leproust
Twist Bioscience

James Brown

James Brown
SynBio-SIG

Jason King

Jason King
Oxford Biotrans

Jerome Engel

Jerome Engel
Lean Launchpad

Karen Ingram

Karen Ingram
CUT/PASTE/GROW

Karl Handelsman

Karl Handelsman
Codon Capital

Lisa Caproni

Lisa Caproni
Touchlight Genetics

Markus Gershater

Markus Gershater
Synthace

Max Hodak

Max Hodak
Transcriptic

Michael Florea

Michael Florea
SynBIC

Michael Roberts

Michael Roberts
Synpromics

Mike Koeris

Mike Koeris
Sample6

Oliver Sexton

Oliver Sexton
Rainbow Seed Fund

Omri Amirav-Drory

Omri Amirav-Drory
Twist Bioscience

Patrick Finn

Patrick Finn
Twist Bioscience

Paul Freemont

Paul Freemont
SynbiCITE

Philippe Gabant

Philippe Gabant
Syngulon

Piers Millet

Piers Millet
Biosecure

Rachel Haurwitz

Rachel Haurwitz
Caribou Bioscience

Richard Kitney

Richard Kitney
SynbiCITE

Riley Doyle

Riley Doyle
Desktop Genetics

Rob Carlson

Rob Carlson
Bioeconomy Capital

Robert McIntyre

Robert McIntyre
TeslaGen

Rodrigo Martinez

Rodrigo Martinez
IDEO

Spencer Adler

Spencer Adler
Bioeconomy Capital

Stephan Herrera

Stephan Herrera
Evolva

Stephen Chambers

Stephen Chambers
SynbiCITE

Thomas Landrain

Thomas Landrain
PILI

Toby Richardson

Toby Richardson
Synthetic Genomics

Advisory Committee

James Brown

James Brown
SynBio-SIG

Lisa Caproni

Lisa Caproni
Touchlight Genetics

Stephen Chambers

Stephen Chambers
SynbiCITE

John Collins

John Collins
SynbiCITE

John Cumbers

John Cumbers
SynBioBeta

Tim Fell

Tim Fell
Synthace

Paul Freemont

Paul Freemont
SynbiCITE

Richard Kitney

Richard Kitney
SynbiCITE

Mike Koeris

Mike Koeris
Sample6

Schedule:

Wednesday April 22nd, 2015 

The Lean LaunchPad technique, first pioneered in software engineering, has recently been used at Imperial College London for synthetic biology startup creation. Come discover the lessons learned from the top three teams who took part in the program as they share their pitfalls and breakthroughs.

In 1996, Tom Knight presented to DARPA a set of slides that became the basis for what we now call the Field of the Synthetic Biology.  Later, his PhD student at the time, Ron Weiss together with Tom, laid the foundations for the scientific pursuit of reliably-engineered biological systems.  In this Fireside Chat, Tom and Ron will look back on the last 20 years of the field and look forward to the next 20 years.

Speakers: Tom Knight, Ginkgo Bioworks & Ron Weiss, MIT

Without investment, no biotech company could ever get off the ground. But what are investors looking for? What is the best stage to raise capital, and who should you be talking to? What are the global trends in synthetic biology investment and how will they affect the industry? Whether you are an entrepreneur with a plan, an investor with a checkbook, or a CEO with acquisition plans, this is the panel for you.

Moderator: Josko Bobanovic, Sofinnova
Panelists:
Veronique de Bruijn, IcosCapital,  Katrin Burt, Syngenta, Karl Handelsman, Codon Capital, Kathryn Owen, Imperial Innovations, Oliver Sexton, Midven

No one knows what the future will bring, but this session will give you a pretty good idea. Covering the present and future of synthetic biology, tackling problems from food, vitamins, information storage, to high-value molecule fermentation for the production of biofuels and specialty chemicals. Our speakers will give an insight into the bleeding edge of innovation.

Moderator: Rosalind Le Feuvre, SYNBIOCHEM
2:55PM – 3:05 PM: Rémi Bernard, Deinove
3:05 PM – 3:15 PM: Hans Genee, Biosyntia
3:15 PM – 3:25 PM: Stephan Herrera, Evolva
3:25 PM – 3:35 PM: Darren Platt, Amyris
3:35 PM – 3:45 PM: Axel Trefzer, Thermo Fisher

This is a seminal moment in the history of biology.  Our ability to read, write, and rewrite the DNA code of life makes it possible to engineer all manner of organisms ranging from microbes to plants to insect to animals.  Similar to semiconductor technology that gave rise to smartphones and the web, the powerful tool of synthetic biology gives us the ability to discover solutions that make life better – whether it is apples that don’t brown, customized anti-aging products made from your own DNA, or biomaterials generated from waste.  In this fireside chat, Ena and Daisy will discuss the game-changing possibilities and implications of synthetic biology for consumer products , and ask what good design might mean in this space.

Speakers: Ena Cratsenburg, Intrexon & Alexandra Daisy Ginsberg, Royal College of Art

Thursday April 23rd, 2015

Dive into the minds of the most progressive companies in the industry. Hear about how they have pushed the envelope to make biology easier to engineer through automation, synthesis, and new tools enabling the bioeconomy. A variety of recent developments will be shared, from new hardware devices to new ways to synthesize DNA through to high-throughput testing and production.

Come learn how synthetic biology is helping to construct the latest pharmaceuticals and is improving lives through novel healthcare products. Staying competitive is key as new companies are entering the market with cutting edge tools and solutions. This session will also give you insight into how pharma and healthcare companies are retooling to increase productivity and rate of discovery.

In this interactive panel, you will gain access to investors in synthetic biology as they share their experience, with a particular focus on those funding companies based in the U.K. and Europe. Discussions will include specific investment trends as well as valuable insight into where the industry is heading.

In this lightning talk session, you will have a chance to hear from the newest startups in the synthetic biology community, receive critical updates from the industry’s leading companies, and discover upcoming trends. All in addition to receiving a current market overview of the industry.

Join us as we cover the ever-changing landscape of policy and international strategies. We will explore current and future strategies as the panel delves into what it takes to keep the synthetic biology industry thriving.

Synthetic biology is maturing as a discipline as ideologies are iterated, products come to market and design complexity increases. Now the sweeping promises of a biological future need iteration too. What are we going to design with biology? This panel provides multiple perspectives on the potential role of design in biology.

Partners: